NASDAQ:INO

Inovio Pharmaceuticals Inc (NASDAQ:INO) Shows Encouraging Results Of INO-5401 In Combination With cemiplimab In Phase 2 Study

In phase 2 study of INO-5401 in combination with cemiplimab, Inovio Pharmaceuticals Inc (NASDAQ:INO) achieved success in ensuring the progression-free survival of patients who are diagnosed with GBM (glioblastoma multiforme). The phase 2 study is conducted using INO 9012, and INO 5401 in combination with a PD-1 blocking antibody – Libtayo on fifty-two patients diagnosed […]